Overview

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent malignant glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New Approaches to Brain Tumor Therapy Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Camptothecin
Irinotecan